Riskpilot← Back to searchSign inGet full accessErGe BioTech AB
ABActiveOrg 5569728750GöteborgComputer consultancy and computer facilities management activities · NACE 6220Est. 20141 employees
Revenue 2025
SEK 1,3M
-3% vs 2024
EBITDA margin
11.6%
-43% vs 2024
Equity ratio
40.1%
Financial strength
Net profit 2025
SEK 163K
-21% vs 2024
| Revenue | SEK 1,3M | -3% |
| EBITDA | SEK 148K | -43% |
| Net profit | SEK 163K | -21% |
| Total assets | SEK 1,1M | -48% |
| Equity | SEK 421K | -75% |
| Employees | 1 | — |
Legal name
ErGe BioTech AB
Org number
5569728750
Legal form
Aktiebolag
NACE code
6220 · Computer consultancy and computer facilities management activities
Founded
27 maj 2014
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva utbildnings och konsultverksamhet inom konsulting, rekrytering, bemanning, projektarbete. Bolaget skall även bedriva utveckling, underhållning och försäljning av produkter och tjänster relaterade till Bioteknik, Informationsteknik och därmed förenlig verksamhet.
Address
Göteborg
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 352 | 1 308 | 1 324 | 1 317 | 1 279 |
| Staff expenses | — | −519 | −597 | −634 | −806 |
| EBITDA | 475 | 457 | 404 | 260 | 148 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 475 | 457 | 507 | 260 | 148 |
| Net financials | — | −1 | −1 | 1 | 2 |
| Profit before tax | 475 | 341 | 378 | 261 | 209 |
| Tax | −102 | −71 | −79 | −56 | −47 |
| Net profit | 373 | 270 | 299 | 206 | 163 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 216 | 1 495 | 1 832 | 2 004 | 1 052 |
| Equity | 746 | 916 | 1 302 | 1 714 | 421 |
| Long-term debt | 0 | 55 | 57 | 57 | 44 |
| Short-term debt | 290 | 228 | 166 | 53 | 249 |
| Total debt | 290 | 284 | 223 | 110 | 293 |
EBITDA margin
11.6%
This company
15.8%
Market median
-27% vs market
20212025
Equity ratio
40.1%
This company
38.2%
Market median
+5% vs market
20212025
Return on equity
38.6%
This company
18.4%
Market median
+110% vs market
20212025
Net profit margin
12.7%
This company
8.1%
Market median
+57% vs market
20212025
Asset turnover
1.22×
This company
1.12×
Market median
+9% vs market
20212025
Debt / equity
1.50×
This company
0.62×
Market median
-142% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EG Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ErGe BioTech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erna Gredelj | Chief Executive Officer | 0 companies |
| Ermina Karabasic | Deputy Board Member | 0 companies |
| Enes Gredelj | Deputy Board Member | 0 companies |